

Broadlane Signs Agreement for New Generation Cordis Coronary and Endovascular Treatment Products

SAN FRANCISCO, CA, and WARREN, NJ – March 13, 2002 – Broadlane Inc. and Cordis Corporation, a Johnson & Johnson company, today announced that Broadlane has awarded nine individual agreements for Cordis to provide its new generation coronary and endovascular products to Broadlane's healthcare customers.

Cordis coronary stent products now available to Broadlane customers include the Cordis Cardiovascular Bx VELOCITY™ Stent and the Bx VELOCITY™ Stent with HEPACOAT™ (Carmeda® Endpoint-attached Heparin), the first and only stent with heparin coating approved in the U.S.

Cordis endovascular stent products now available to Broadlane customers include the Cordis Endovascular self-expanding S.M.A.R.T.® Transhepatic Biliary Stent with MicroMarker Technology, the newly released PALMAZ® GENESIS™ Transhepatic Biliary Stent, and a full line of peripheral stents.

Additional products covered by these agreements include a wide variety of Cordis Endovascular PTA Balloons such as the POWERFLEX™ P3, OPTA™ PRO, MAXI™ and SLALOM™; AVIATOR™ PTA Dilatation Catheters; a complete line of cardiology and endovascular guiding catheters, diagnostic guidewires, sheath introducers and interventional sheaths; and a number of other cardiology and endovascular core product brands from its broad-based portfolio.

- more -

Broadlane Signs Agreement for New Generation Cordis Coronary and Endovascular Treatment Products

Page 2

“Broadlane is diligent in selecting vendors to help it achieve its goal of providing the best health services possible in a cost-effective manner,” said Donal O’Dwyer, Worldwide President, Cordis Cardiology. “We are pleased to continue our relationship with Broadlane and look forward to expanding this association by offering innovative breakthrough products that enhance their customers’ procedural capabilities.”

Cordis was awarded the contracts as part of Broadlane’s intensive contract selection process, which focuses on delivering high-quality, cost-effective solutions to Broadlane’s hospital and other healthcare customers. To ensure that it selects the best products and vendors for its customers, Broadlane solicits input and direction from key end users, such as physicians and nurses, as well as hospital business leaders.

“Broadlane’s selection of Cordis and its vascular product line represents our continuing effort to provide our customers with solutions that meet their needs,” said Eva Challis of Broadlane’s contracting services department. “Cardiovascular care represents one of the most expensive areas in healthcare delivery and Cordis offers products and services in line with our mission to improve quality and reduce cost.”

The agreements became effective Feb. 1, 2002. Under terms of the agreements, Broadlane will offer the newest available technology nationwide to their customer facilities for patients with severe coronary artery disease. Cordis Cardiology’s new generation Bx VELOCITY™ Coronary Stent, centerpiece of these Broadlane-Cordis agreements, was approved by the U.S. Food and Drug Administration (FDA) in May 2000 for abrupt and threatened closure of blocked arteries. More recently, the Bx VELOCITY™ Coronary Stent received FDA approval for elective treatment of blocked arteries (*de novo* and restenotic lesions) in native coronary arteries 3-5 mm in diameter and up to 30 mm in length.

- more -

Broadlane Signs Agreement for New Generation Cordis Coronary and Endovascular Treatment Products

Page 3

“We value Broadlane’s confidence in our products and services and remain committed to providing the best vascular solutions for physicians and their patients,” said Carol L. Zilm, Worldwide President, Cordis Endovascular. “This new Broadlane award to Cordis will help provide Broadlane clinicians and administrators with high-quality products and technology. In addition, these agreements are designed to help achieve significant cost reductions for the healthcare organizations.”

About Broadlane

Through an extensive suite of services, Broadlane delivers comprehensive supply chain management services to the healthcare industry. Those services include contract management, procurement strategy consulting, materials management outsourcing, and technology services. Among the companies that focus on improving efficiencies within the healthcare supply chain, only Broadlane offers this full array of services.

Broadlane customers include leading healthcare providers such as Kaiser Permanente, Tenet Healthcare Corporation (NYSE: THC), Universal Health Services (NYSE: UHS), Continuum Health Partners, The Health Alliance of Greater Cincinnati, Community Health Systems (NYSE: CYH), U.S. Oncology (NasdaqNM: USON), Alliance Imaging Inc. (NYSE: AIQ) and others. Broadlane counts among its customers more than 300 acute care hospitals and more than 1,400 sub-acute care facilities. Broadlane has offices in San Francisco and Oakland, Calif.; Cincinnati; Dallas; and New York City. For more information, visit www.broadlane.com.

About Cordis

Cordis Cardiology and Cordis Endovascular are units of Cordis Corporation. Cordis is a leading developer and manufacturer of products for interventional medicine, minimally invasive imaging, and electrophysiology. Cordis Corporation has been a pioneer in circulatory disease management since its founding in 1959. In 1996, it merged with Johnson & Johnson to form Cordis, a Johnson & Johnson company, with approximately 3,500 employees worldwide. For more information, contact www.cordis.com.